A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011

Journal of Infectious Diseases

Volumn 207, Issue 6, 2013, Pages 966-973

  Garg, Shikha ^a   Moore, Zack ^b   Lee, Nicole ^b   McKenna, John ^a   Bishop, Amber ^a   Fleischauer, Aaron ^b   Springs, Chasisity B ^c   Nguyen, Ha T ^a   Sheu, Tiffany G ^a   Sleeman, Katrina ^a   Finelli, Lyn ^a   Gubareva, Larisa ^a   Fry, Alicia M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c SOUTH CAROLINA DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL   (United States)

Author keywords

antiviral resistance; influenza B virus; neuraminidase substitution; oseltamivir

Indexed keywords

ISOLEUCINE; OSELTAMIVIR; VALINE; VIRUS SIALIDASE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIC; FEMALE; HUMAN; INFANT; INFLUENZA B; INFLUENZA VIRUS B; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; FEMALE; HUMANS; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; NORTH CAROLINA; OSELTAMIVIR; SOUTH CAROLINA; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84874223618     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis776     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morbidity and Mortality Weekly Report 2010; 59:1057-62.
2. Centers for Disease Control and Prevention. Influenza-associated pediatric deaths-United States, September 2010-August 2011. MMWR Morbidity and Mortality Weekly Report 2011; 60:1233-8.
3. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. The Journal of Infectious Diseases 2012; 205:895-905.
4. Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerging Infectious Diseases 2011; 17:2043-6.
5. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. The Journal of Infectious Diseases 1998; 178:1257-62.
6. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA: The Journal of the American Medical Association 2007; 297:1435-42.
7. Hurt AC, Iannello P, Jachno K, et al. Neuraminidase inhibitor-resistant and-sensitive influenza B viruses isolated from an untreated human patient. Antimicrobial Agents and Chemotherapy 2006; 50:1872-4.
8. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. The Journal of Infectious Diseases 2006; 193:760-4.
9. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Research 2010; 85:354-60.
10. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy 2008; 52:3284-92.
11. Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2008; 41:25-8.
12. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. The Journal of Infectious Diseases 2011; 204:1848-56.
13. CDC. FluView: week ending May 19, 2012. Atlanta, GA: US Department of Health and Human Services, CDC, 2012. http://www.cdc.gov/flu/weekly. Accessed 25 May 2012.
14. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial Agents and Chemotherapy 2006; 50:2395-402.
15. Hurt AC, McKimm-Breschkin JL, McDonald M, Barr IG, Komadina NHampson AW. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Research 2004; 103:205-11.
16. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. The Journal of Infectious Diseases 2004; 190:1627-30.
17. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitorresistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrobial Agents and Chemotherapy 2005; 49: 4075-84.
18. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Research 2002; 54:143-7.
19. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Research 2004; 103:195-7.
20. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2006; 43:439-44.
21. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2007; 44:197-202.
22. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2008; 47:339-45.
23. American Academy of Pediatrics Committee on Infectious D. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813-25.
24. Centers for Disease C, Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morbidity and Mortality Weekly Report 2011; 60:1128-32.